The Food and Drug Administration approved it in 2017 for adults with Type 2 diabetes
If you're in Willow Street and considering oral semaglutide for weight loss, it's designed for adults with a BMI of 30 or higher, or 27 and up with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol
The result is a significant breakthrough in dual-targeted GLP-1 and GIP drugs that reduce HbA1c and body weight more effectively than GLP-1 RA
Kidney failure due to remote organ damage Several risk factors such as genetics, obesity, diabetes, cardiovascular disease, and age can increase the chances of an individual to develop kidney disease, or when already diagnosed, it can gradually drive the progression of the disease (Kazanciolu 2013)
This may require prior authorization or proof of previous failed treatments